SynVivo

What SynVivo does

SynVivo Inc. is a privately-held US company headquartered in Huntsville, Alabama, that develops and sells organ-on-a-chip and microfluidic cell-based assay platforms for drug discovery, toxicology, and translational research. Its core technology centers on synthetic microvascular network (SMN) chips that replicate in vivo microvasculature with dynamic flow and shear stress conditions, supporting five specialized organ models: SynBBB (blood-brain barrier), SynTumor (cancer-on-a-chip), SynALI (lung/air-liquid interface), SynRAM (inflammation/leukocyte-endothelium), and SynTox (toxicology), plus a newer multiorgan brain-lung platform. Supporting instruments include pneumatic primers, cell impedance analyzers, syringe pumps, and stage top incubators, alongside microfluidic chips (linear, bifurcating, idealized networks), accessories, custom assay development services, and workshops.

The company sells through a direct e-commerce storefront (synvivobio.com) complemented by a global distributor network, targeting pharmaceutical and biotechnology companies as well as academic and research institutions. Pricing is quote-based across all products and services, with terms of 30 days from invoice date and FOB facility shipping. Products are explicitly labeled for research use only, not for human or animal therapeutic or diagnostic use. SynVivo has built scientific credibility through over 50 peer-reviewed publications in journals including PNAS, Journal of Controlled Release, and Analytical Chemistry, and was recognized as a Top 10 Innovation of 2013 by The Scientist magazine. The company operates with fewer than 10 employees, has no disclosed funding rounds or investors, and is governed under Delaware law.

Leadership consists of Gwen Fewell, PhD as President and CEO; Balabhaskar Prabhakarpandian, PhD as CTO; Deborah Ramsey, PhD as Director of Scientific Development; and Shreyas Galkwad, PhD as Research Scientist. The company's positioning aligns with regulatory tailwinds from the FDA Modernization Act and New Approach Methodologies (NAMs), and from European animal testing restrictions, positioning its human-relevant in vitro models as alternatives to traditional animal-based preclinical testing.

Name

SynVivo

Legal name

SynVivo Inc.

Website

https://synvivobio.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

SynVivo Inc. develops organ-on-a-chip and microfluidic cell-based assay platforms, including five specialized organ models (BBB, tumor, lung, inflammation, toxicology) and supporting instruments, selling to pharmaceutical companies and academic researchers via direct e-commerce and a global distributor network.

Ownership category

akta.pro rank

Product category

Organ-on-Chip Technology Platforms

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)

SIC

Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Organoids & Organ-on-Chip (regenerative models) (HLAAAGAD)

akta.pro secondary industry

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)

Keywords

• Organ-on-chip models
• Microfluidic cell assays
• Drug discovery platforms
• In vitro tissue models
• 3D cell culture

Headquarters

HQ city

Huntsville

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. 3D Tissue and Organ-on-Chip Products: Sale of ready-to-use organ-on-chip models including SynBBB, SynTumor, SynALI, SynRAM, and SynTox for drug discovery and research applications.
2. Microfluidic Chips and Instruments: Sale of microfluidic chips (linear channels, bifurcating channels, microvascular networks) and supporting instruments (pneumatic primer, cell impedance analyzer, syringe pumps, stage top incubators).
3. Screening and Assay Development Services: Custom assay development and screening services for specific research requirements using SynVivo platforms.
4. Workshops and Training: Educational workshops and training programs on organ-on-chip technologies and applications.
5. Accessories: Sale of supporting accessories for microfluidic experiments and cell culture.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

SynVivo develops and sells cell-based microfluidic organ-on-a-chip platforms that replicate native tissue microenvironments with dynamic flow and shear stress conditions for drug discovery, toxicology, and translational research. The product portfolio includes ready-to-use 3D organ models (SynBBB, SynTumor, SynALI, SynRAM, SynTox), microfluidic chips, supporting instruments, and accessories, complemented by custom screening/assay development services and training workshops for the pharma, biotech, and academic research communities.

Differentiator

Problem solved

Functional benefit

Products and services

• SynBBB 3D Blood Brain Barrier Model
• SynRAM 3D Inflammation Model Inflammation-on-a-chip platform for immunology and inflammation researchers studying leukocyte-endothelium interactions, rolling adhesion, and migration under physiological flow.
• SynTumor 3D Cancer Model Cancer-on-a-chip platform for oncology researchers visualizing 3D tumor cluster growth, tumor perfusion via vascular network, and real-time drug delivery monitoring.
• SynALI Lung Model Small airway lung-on-a-chip model for respiratory researchers supporting air-liquid interface culture with ciliated cells and mucus production for studying respiratory infection and barrier function.
• SynTox 3D Toxicology Model 3D toxicology platform for safety assessment researchers featuring a complete vascular lumen under flow for studying systemic toxicology and immunotoxicology responses.
• Microfluidic Chips Standalone microfluidic chip products including linear channels, bifurcating channels, microvascular networks, and idealized networks for researchers building custom cell-based assays.
• Instruments Supporting laboratory instruments for organ-on-chip workflows, including pneumatic primer, cell impedance analyzer, syringe pumps, and stage top incubators for researchers operating the SynVivo platforms.
• Accessories Supporting accessories for microfluidic experiments and cell culture, sold as consumables and complementary items for SynVivo platform users.
• Screening & Assay Development Services Custom assay development and screening services for pharmaceutical, biotechnology, and academic research teams with specific experimental requirements using the SynVivo platforms.
• Workshops & Trainings Educational workshops and training programs on organ-on-chip technologies and applications, targeted at researchers and laboratory teams adopting SynVivo platforms.

Quantifiable outcome

• Cells cultured in SynVivo chips retain physiological function and gene expression patterns comparable to in vivo
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Scale indicators1 record

Expansion highlights5 records

Direct peers

• TissUse: TissUse develops multi-organ chip systems (Humimic) for systemic substance testing, a directly comparable approach to SynVivo's multiorgan brain-lung platform in the preclinical toxicology and ADME use case.
• Emulate: Emulate is a venture-backed organ-on-chip company offering the Liver-Chip, Intestine-Chip, Lung-Chip, and Brain-Chip. It is the most directly comparable competitor to SynVivo in target customer (pharma/biotech), product category (microfluidic organ-on-chip), and use case (preclinical drug safety and efficacy).
• Nortis: Nortis produces organ-on-chip microfluidic platforms (chips, instruments, and services) for kidney, vascular, and toxicology applications—closely aligned with SynVivo's microfluidic chips and instruments portfolio and customer base.
• CN Bio: CN Bio provides organ-on-chip systems including the PhysioMimix platform for liver, lung, and multi-organ applications targeting pharmaceutical toxicology and disease modeling—directly overlapping with SynVivo's SynTumor, SynALI, SynTox, and multiorgan offerings.
• Mimetas: Mimetas offers the OrganoPlate, a microfluidic 3D cell culture platform for organ-on-chip applications including kidney, intestine, and tumor models, competing directly with SynVivo in the pharma/biotech drug discovery segment.

Emerging players

• InSphero: InSphero provides 3D cell-based assay platforms including microtissue models for liver, pancreas, and tumor applications. Adjacent to SynVivo's organ-on-chip focus, with overlap in drug discovery and toxicology end markets but a different underlying technology (spheroid vs. microfluidic).
• Kirkstall: Kirkstall manufactures the Quasi Vivo interconnected cell culture system for organ-on-chip and multi-organ applications, serving the same pharma/biotech research customer base as SynVivo.
• React4Life: React4Life develops organ-on-chip and 3D cell culture technologies including the MIVO platform for multi-organ fluidic modeling, directly overlapping with SynVivo's multiorgan fluidic interconnection capabilities.

Others

• Organovo: Organovo develops 3D bioprinted human tissues for preclinical research. While adjacent to SynVivo's organ-on-chip mission, its bioprinting-based approach is technologically distinct, making it more of a thematic peer than a direct competitor.

Broad incumbents

• Thermo Fisher Scientific: Thermo Fisher is a broad life sciences tools incumbent that sells competing cell culture instruments, consumables, and increasingly organ-on-chip-adjacent products. Its massive scale and catalog purchasing motion pose a long-term competitive threat to small specialty vendors like SynVivo.

Market position

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/synvivo-llc
• Xx.com/synvivo

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SynVivo